Intracranial embolism

Summary

Intracranial embolism (MONDO:0006809) is a disease and 8 clinical trials. Top therapeutic interventions include egaptivon pegol. A subtype of ischemic stroke — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intracranial embolism
Mondo ID	MONDO:0006809
EFO	EFO:1000991
MeSH	D020766
DOID	DOID:4372
ICD-11	816982857
SNOMED CT	75543006
UMLS	C0752140
MedGen	155710
Is cancer (heuristic)	no

Disease family

This is a subtype of ischemic stroke. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebrovascular disorder › stroke disorder › ischemic stroke › intracranial embolism

Related subtypes (4): cerebral infarction, transient ischemic attack, brain stem infarction, pediatric arterial ischemic stroke

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE3	2
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00862160	PHASE4	UNKNOWN	Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit
NCT00336596	PHASE3	UNKNOWN	Ultrasound Enhanced Thrombolytic Therapy of Middle Cerebral Artery Occlusion
NCT03001960	PHASE3	UNKNOWN	Dual AntiPlatelet Therapies for Prevention of Periinterventional Embolic Events in TAVI
NCT00742612	PHASE2	TERMINATED	Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy
NCT01752946	Not specified	UNKNOWN	A Registry Study of Shuxuening Injection Used in Hospitals in China
NCT02321917	Not specified	COMPLETED	Rheoparin-coated Tubing System for Minimized Extracorporeal Circulation (MECC)
NCT02758964	Not specified	COMPLETED	Evaluation of Cerebral Thrombembolism After TAVR
NCT02955004	Not specified	COMPLETED	Electrical Cardioversion of Recent Onset Atrial Fibrillation - Silent Thromboembolic Events, Reverse Atrial Remodeling

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EGAPTIVON PEGOL	2	1